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Heat shock proteins (HSPs) are important molecules required for ideal protein function. Extensive research on the functional
properties of HSPs indicates that HSPs may be implicated in a wide range of physiological functions including immune function.
In the immune system, HSPs are involved in cell proliferation, differentiation, cytokine release, and apoptosis.Therefore, the ability
of the immune system, in particular immune cells, to function optimally and in unison with other physiological systems is in part
dependent on signaling transduction processes, including bidirectional communication with HSPs. Regulatory T cells (Tregs) are
important T cells with suppressive functions and impairments in their function have been associated with a number of autoimmune
disorders. The purpose of this paper is to examine the relationship between HSPs and Tregs. The interrelationship between cells
and proteins may be important in cellular functions necessary for cell survival and expansion during diseased state.
1. Introduction
Optimal cellular function is regulated by several molecules
including heat shock proteins (HSPs). These proteins have
chaperone properties and are important in both stressed and
unstressed cells. HSPs can be categorized into six diverse
highly or less-conserved families. These include HSP10,
HSP40, HSP60, HSP70, HSP90, and HSP100 [1–4]. HSP60 is
found in themitochondria [5]. HSP70 is implicated in protein
transport assembly and synthesis. It has anti-apoptotic prop-
erties that are implicated in intrinsic and extrinsic apoptotic
pathways. HSP70 interacts with the mitochondria through
death receptor signaling where it binds to death receptors
DR4 and DR5 impeding TNF-related apoptosis inducing
ligand (TRAIL) [6]. Importantly, HSP70 can bind to either
the unphosphorylated C terminus of protein kinase C or Akt
prompting rephosphorylation and kinase stabilization [7].
ATP-dependent HSP90 regulates cell survival by stabilizing
kinases such as Akt and suppressing apoptosis by inhibiting
caspases [8, 9]. The exact structural domains for all human
HSPs remains to be determined; however, HSP70 and HSP90
have been well characterized. HSP70 is comprised of an N-
terminal nucleotide-binding domain with ATPase activity
and a C terminal containing a substrate-binding domain [10–
12]. HSP90 on the other hand has three characterized struc-
tural domains including an N-terminal nucleotide-binding
domain, a middle segment and a C terminus [13–16]. Inter-
domain interactions occur by a conserved linker [17].
HSPs are found in intracellular and extracellular spaces
as well as in the circulation. Intracellular HSPs including
HSP27, HSP70, and HSP90 have direct roles in preventing
protein aggregation, induction of cell death pathways, cellular
rescue and maintaining receptor interactions [18]. These
HSPs may be overexpressed in most cancers promoting the
growth and survival of tumor cells. The downregulation of
their expression results in a substantial decrease in tumor
cells [3, 19–21]. Extracellular HSPs, HSP70, HSP90, and gp96
are peptide carriers, inducers of cytokines, and stimulants
for immune cells during stress [18]. These HSPs may be
either membrane bound to the plasmamembrane or released
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into the circulation [9]. In general, there are two sources
of extracellular HSPs, pathogen- and human-derived HSPs.
Pathogen derived HSPs are found in the extracellular space
as a consequence of infection while human-derived HSPs
are released into the extracellular space in the event of
intracellular traumas such as apoptosis or necrosis [8].
Extracellular HSPsmay be attached to the plasmamembrane.
Additionally, extracellular HSPs induce the maturation of
dendritic cells and present peptide molecules to antigen-
presenting cells (APCs) thus, linking the innate immune and
adaptive immune systems. Cell-free or circulating HSPs, for
instance, HSP70, are released into the circulation by glial
cells, B cells, PBMCs, or following necrosis [22–25]. These
HSPs can be found in the serum and plasma. Cytokines,
interferon (IFN)-𝛾 and IL-10, can cause the release of HSP70
from exosomes [26]. Thus, HSP70 may serve as molecular
markers of diseases such as acutemyocardial infarctionwhere
these HSPs are unduly expressed in the circulation [27].
In unstressed cells, HSPs are chaperone proteins that
maintain protein configuration and transport. The presence
of HSPs is advantageous especially during cell stress owing to
the versatility in their functional attributes, encompassing the
inhibition of protein processing, regulation, and production
[28, 29]. In the incident of stress, the heat shock functional
domain and heat shock transcription factors (HSFs), includ-
ingHSF-1, HSF-2, HSF-3, andHSF-4, are activated ensuing in
the stimulation of the heat shock response (HSR) [30]. HSF-
1 translocates into the nucleus oligomerizes, phosphorylates,
and binds to heat shock elements causing the release of RNA
polymerase [31, 32]. The heat shock functional domain is
comprised of a nucleotide-binding domain and a peptide-
binding domain. Hydrolysis of ATP to ADP occurs when it
binds to the adenine nucleotide-binding domain causing a
structural change and detachment of substrates. The peptide
domain interacts with the hydrophobic substrates [33].
A set of HSPs known as small HSPs have also been
identified to have an involvement in the immune system;
nonetheless, this paper is limited to HSPs and not small
HSPs.
2. Heat Shock Proteins and
the Immune System
The immune system is an intricate network of cells and
proteins, and bidirectional communication between different
components of the immune system is necessary for optimal
homeostasis. HSPs are implicated in both the adaptive and
innate immune systems. In the innate immune system, HSPs
stimulate dendritic cells andmacrophages, as these are APCs,
they consecutively stimulate adaptive immune cells [34, 35].
HSPs are important in NK cell function as they are known
to increase cytotoxic function and cell proliferation [36].
In particular, membrane-bound HSP70 on various cancer
cells is recognized by cluster of differentiation (CD)94 on
the NK cell, initiating effective cytolysis of the tumor cells
[37, 38]. HSPs may induce the secretion of either anti- or
proinflammatory cytokines thereby monitoring the immune
response [39, 40].
HSPs may serve as immunogens released in response to
an inflammatory episodes which associates with particular
surface receptors to induce adaptive immune reactions [39,
41–44]. Antigenic binding of HSPs occurs via interactions
between hydrophobic residues such as the V436 in DnaK
and bound peptides hence, mutations in these residues may
obscure adaptive immunity as a consequence of loss in
binding abilities of the peptide [45]. Similarly, HSPs increase
the effectiveness of cross-presentation between antigens and
APCs in the extracellular milieu, perpetrating in the presen-
tation of peptides to major histocompatibility complex class
one (MHCI) or MHCII molecules on T cells. CD91, an HSP
receptor, is a requisite for this process and increases T-cell-
mediated responses related to T helper (Th)1, Th2, and Tregs
[9]. Thus, in the presence of tumors, concomitant relations
between the extracellular HSPs and the APCs following
internalization of the tumor peptides via CD91 pathway
generate both anti-and proinflammatory immune response
mediated by T cells [46].
Incidentally, extracellular HSPs may have potent
cytokine-related properties necessary for immune response.
They act via the association with pattern recognition
receptors (PRR) including toll-like receptors (TLRs) and
CD14. CD14 is a lipopolysaccharide membrane protein
receptor lacking a transmembrane or an intracellular
domain [47]. CD14 is a necessary stimulant for HSP60 and
HSP70. Following stimulation, these extracellular HSPs are
endocytosed causing calcium influx and phosphorylation
[48]. Myeloid differentiation primary response gene (MYD)
88 associates with the cytoplasmic domain of the TLR
while interleukin (IL)-1 receptor-associated kinase (IRAK)
is recruited, phosphorylated, and released. IRAK interacts
with the tumor necrosis factor (TNF) receptor-associated
factor 6 (TRAF6). This is sequentially followed by the
stimulation of transforming growth factor-𝛽-activated
protein kinase 1 (TAK1) [49]. TAK1 stimulates I𝜅B Kinase
(IKK) and this phosphorylates I𝜅B prompting the movement
of nuclear factor kappa-light-chain enhancer of activated
B cells (NF𝜅B) to the nucleus where it binds to target
genes. NF𝜅B modulates the transcription of cytokine genes
including TNF-𝛼, IL-1𝛽, IL-6, and IL-12 [50]. The generation
of NF𝜅B elicits sequences of events altering the expression
of cytokines, chemokines, cell adhesion molecules, growth
factors, anti-apoptotic proteins, and immune receptors [51].
HSP may repress NF𝜅B successively decreasing TNF-𝛼
[52]. This occurs via mitogen-activated protein kinases
(MAPK) pathway originating in the phosphorylation of
c-Jun, which sequentially stimulates activator protein (AP)-1
and upregulates proinflammatory IL-18. Similarly, excess
secretion of IL-18 is regulated by HSR which suppresses
IL-18, by inhibiting JNK/MAPK signaling [53].
The multifaceted nature of HSPs incorporates the regula-
tion of reactive oxygen species (ROS) and some chemokines
from stimulated monocytes, macrophages, and dendritic
cells. Equally, heightened HSP antigen presentation in APCs
is correlated with an increase in CD86, CD40, and MHC
molecules [9, 54]. HSP60 expressively inhibits chemo-
taxis and in combination with TLRs upregulates anti-
inflammatory reactions while altering B-cell activity [55,
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56]. Involvement of HSPs in the mechanism of danger-
activated molecular pattern (DAMPS) is controversial as
they have been described as DAMPs while elsewhere they
have been implicated in the dampening of DAMPS owing to
their interactions with TLRs thus, inducing proinflammatory
responses [57, 58]. DAMPS are intracellular endogenous
molecules secreted following necrosis with the ability to
induce nonspecific adaptive immune responses following
dendritic cell activation. DAMPS may also interact with
pattern recognition receptors (PRRs) resulting in the pres-
ence of inflammatory cytokines [59]. In mice, macrophages
stimulated with LPS release high mobility group box 1
(HMGB1) sequestering a proinflammatory response which
effectively prompts apoptosis [60]. In the presence of HSP,
HMGB is not translocated to the nucleus averting induction
of the apoptotic pathway; thus, cell death is aborted [61].
Similarly, HSF-1 binds to the promoter regions of cytokine
genes such as TNF-𝛼 and IL-1𝛽 in mice, inhibiting TNF-𝛼
expression in macrophages [62]. TNF-𝛼 is involved in the
TRAIL death receptor pathway and perhaps obscures their
production preventing nonspecific cell death that may be
harmful to the immune response or arouse an overreactive
immune response that activates autoimmunity.
In autoimmune diseases, HSPs may be important in
regulating T-cell-related cytokine dominance from a primar-
ily proinflammatory to an anti-inflammatory state [40, 63–
65]. High incidence of HSP70 decreases endotoxin-induced
protein and mRNA levels of TNF-𝛼 in heat-induced peri-
toneal macrophages [66] suggesting an influence of HSPs
on the transcription of these genes. However, overexpression
of HSP70 by peripheral blood macrophages decreases LPS-
induced TNF-𝛼, IL-1𝛽, IL-10, and IL-12 [67]. Additionally,
HSP70 alters proinflammatory cytokine production increas-
ing endotoxin tolerance and survival [68].
3. The Role of Heat Shock Proteins in
Regulatory T Cell Function
Regulatory T cells (Tregs) are a subset of CD4+ T cells with
suppressive functions. Two main groups of Tregs have been
characterized based on their site of development, that is, in
the thymus (natural Tregs (nTregs)) and in the periphery
(inducible Tregs (iTregs)) [69]. NTregs are derived from
bone marrow progenitor cells transported to the thymus
where they differentiate into nTregs following negative and
positive selection. Following maturation, these cells migrate
to the periphery [70]. NTregs can be differentiated from
other T cells owing to the exclusive expression of forkhead
box P3 (FOXP3) which is necessary for nTreg-suppressive
function [71, 72]. In mice nTregs can be differentiated from
iTregs owing to the presence of high levels of neuropilin-
1 on mice nTregs [73]. Other essential effector and costim-
ulatory molecules that are expressed by these cells include
CD39, CD73, cytotoxic T-lymphocyte antigen 4 (CTLA-
4), lymphocyte-activation gene 3 (LAG-3), CD28, CD80/86,
CD40,OX40 (CD134), and 4-IBB (CD137) [74–76]. ITregs are
generated from naive CD4+ T cells subsequent to induction
by IL-10 and TGF-𝛽 resulting in two populations of iTregs,
type 1 Tregs (Tr1), and T helper 3 (Th3) cells, respectively
[77–79]. Suppressive function of these cells occurs via IL-10
and TGF-𝛽. Peripheral Tregs can also be generated through
interactions between IL-4 or IL-13 and the IL-4R𝛼 [80].
Although, FOXP3 is a characteristic marker of nTregs, Th3
cells can also be induced to generate FOXP3 [81–83]. Upon
activation of the T cell receptor, Tregs suppress dendritic cells,
B cells, macrophages, osteoblasts, mast cells, NK cells, NKT
cells, CD4+ T, and CD8+ T cells [84].
Tregs suppressive mechanisms transpire through
cytokine secretion, cytolysis, metabolic destruction, and
altering of APCs function. The secretion of inhibitory
cytokines such as IL-10, TGF-𝛽, and IL-35 suppresses
immune function. The inhibitory effects of IL-10 occur via
its association with APCs to suppress inflammation hence,
in the absence IL-10-secreting Tregs there is an increase in
inflammation [85]. IL-35 on the other hand suppresses the
expansion of T cells into other T helper subsets, as well as B
cells and macrophages [86, 87]. TGF-𝛽 is necessary for the
survival of Treg subsets [88]. Tregsmay suppress the function
of other cells via granzyme-mediated killing following the
release of granzymes into the target cells [89, 90]. Similarly,
metabolic disruption involving induction of adenosine and
the production of cyclic adenosine monophosphate (cAMP)
may be a vital mechanism for suppressing overreactive cells
[91]. The versatility in Treg effector function allows them
to modulate innate immune cells in particular APCs. This
entails the engagement of surface molecules such as CTLA-4
and LAG-3 with MHCII molecules on the APCs conferring
inhibitory responses that avert the stimulation of other
conventional T cells [92].
As HSPs regulate an extensive component of the immune
system, it is likely that they have a role in the optimal
function of most immune cells. Importantly, the chaperoning
effects of HSPs are necessary for the induction of certain
T-cell phenotypes, importantly, Th1, Th2, and Tregs. This
presupposes that HSPs are important in Treg function. To
date, the following HSPs have been investigated in relation to
Tregs, HSP60, HSP70, and HSP90. HSPs are important in the
induction, proliferation, suppressive function, and cytokine
production of Tregs.
HSP60 employs TLR2-signaling pathway in regulating
Treg function. TLR2 is expressed on the surfaces of Tregs
[93] hence, association between the TLR2 on the Tregs
and the HSP stimulates a sequence of events that affect
the functional properties of Tregs. Incidentally, increasing
levels of HSP60 are correlated with proportional elevations
in the intensity of CD4+ CD25+ Treg-directed suppression
on the production of TNF-𝛼 and IFN-𝛾 [94]. An increase
in HSP60 increases ligand binding of the HSP and the
TLR2, thus, increasing suppression. This may represent an
autoreactive inflammatory response causing autoimmunity
[95]. HSP60 also causes an increase in Treg secretion of TGF-
𝛽 and IL-10 [94]. HSP60 enhances the differentiation of cord
blood cells into CD4+ CD25+ Foxp3+ Tregs [96]. Similarly,
costimulatory signals from p277 also increase the activity
of CD4+ CD25+ Tregs [94]. Therapeutic administration of
HSP60 increases the presence of nTregs, and this is often
correlated with a decrease in atherosclerotic plaques, the
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generation of Tregs, and an increase in the production of
TGF-𝛽 [97, 98]. The concentration of HSP60 affects Treg
suppression and proliferation. Hence, with respect to TLR2
on Tregs, strong ligand binding results in Treg proliferation
while relatively low levels or interactions of ligands and TLR2
on the Treg result in an increase in Treg suppression [99].
Equally,HSP70 inTregs promotes heightened suppressive
function in Tregs [100]. HSP70 confers its activity via TLR4
pathway inducing a surge in the regulatory activities of Tregs.
The TLR4-signaling pathway is important in Treg function,
and thismay be important for FOXP3 induction and suppres-
sion of inflammatory reactions [101]. TLR4 interactions with
HSP70may also augment effector T cell suppression by Tregs
as this has been confirmed in coculture experiments with
other ligands [102]. Additionally, the type of Tregs present
following HSP administration may be dependent on the
type of inflammatory response occurring at the time. For
example in the mice model of arthrosclerosis, immunization
with HSP70 produces a significant amount of CD4+ CD25+
Foxp3+ Tregs [97]. Similarly, adoptive transfer of HSP70
peptide epitopes such as B29 induces antigen-specific FoxP3+
or LAG-3+ CD4+ CD25+ Tregs that are effective in either
aborting or suppressing arthritis in mice [103]. B29 is highly
immunogenic peptides with conserved sequences that are
presented to T cells by MHC II molecules. Immunization
with HSP70 increases IL-10 producing Tregs [104]. HSP70
derived from mycobacterium tuberculosis stimulates the
proliferation of Tregs by acting through dendritic cells
causing a surge in IL-10 while dampening TNF-𝛼 release
[105]. Additionally, HSP70 has anti-inflammatory properties
including down-regulating inflammatory cytokine produc-
tion, increasing cell and tissue tolerance of cytokine-related
cytotoxicity, and influencing the permeability of the epithelial
barrier [106].
HSP90 is important for conserving proteins involved in
signal transduction, via a multichaperone complex [107].
HSP90 can be regulated by histone deacetylases (HDACs)
such as HDAC6, and hypoacetylation of HSP90 occurs in the
presence of excessive HDAC6 [108]. HDAC6 belongs to the
Class II family of HDACs that are necessary for the removal
of acetyl from histones and are found in the nucleus and
cytoplasm [109]. In Tregs, the removal of HDAC6 results
in the overexpression of HSP90 acetylation resulting in an
increase in HSF1-related genes instigating an increase in the
suppressive function of Tregs [100].This may be important in
treating patients with colitis. Mice deficient in HDADC6 are
more likely to have increased levels of Treg suppression due
to the presence of HSP90 and excess Foxp3 [100]. Similarly,
mice deficient in HDAC9 have an increased expression of
Foxp3 [110]. The presence of HDAC9 has been observed
to decrease Foxp3 via deacetylation and incidentally Treg
function. HSP70 not only acts via the TLR4 to regulate Tregs,
but alsomay inhibit HDAC9 ultimately enhancing the release
of Tregs and effective Treg repression [111]. Acetylation is
a necessary posttranslational modification process for pro-
tein production. Hence, increased acetylation of Foxp3 may
avert ubiquitination, increase its regulatory effects, stability,
and promote DNA binding [112, 113]. Therapeutic strategies
involving the use of HSPs to enhance the availability of
Foxp3+ Tregs may be important in autoimmune diseases
while in diseases like cancer it may be necessary to inhibit
Foxp3 acetylation [112].
4. Conclusion
In summary, despite the limited amount of research on Tregs
and HSPs, the available literature suggests an involvement of
HSPs in the suppressive function and cytokine production
of Tregs. HSPs may indirectly or directly stimulate Tregs, via
acetylation, TLR, ligation or act as costimulatory molecules
via the induction of other cells or molecules to stimulate
the Tregs. These may involve cytokines, antigens, and APCs.
Hence, HSPs acting are therefore essential in inducing
Foxp3 expression, cytokine secretion, and mediating Treg
suppressive effects. Additionally, peptides such as B29 may
have therapeutic potential as they are able to suppress
inflammation and maintain tolerance. Thus, the therapeutic
advantage of HSPs relates to their potential use in diseases
where the function of Tregs is impaired, importantly, in the
management of autoimmune diseases.
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